High prevalence of lipoatrophy in pre-pubertal South African children on antiretroviral therapy : a cross-sectional study by Innes, Steve et al.
Innes et al. BMC Pediatrics 2012, 12:183
http://www.biomedcentral.com/1471-2431/12/183RESEARCH ARTICLE Open AccessHigh prevalence of lipoatrophy in pre-pubertal
South African children on antiretroviral therapy:
a cross-sectional study
Steve Innes1*, Mark F Cotton1, Richard Haubrich2, Maria M Conradie3, Margaret van Niekerk4, Clair Edson5,
Helena Rabie5, Sonia Jain6, Xiaoying Sun6, Ekkehard W Zöllner7, Stephen Hough3 and Sara H Browne8*Abstract
Background: Despite changes in WHO guidelines, stavudine is still used extensively for treatment of pediatric HIV
in the developing world. Lipoatrophy in sub-Saharan African children can be stigmatizing and have far-reaching
consequences. The severity and extent of lipoatrophy in pre-pubertal children living in sub-Saharan Africa is
unknown.
Methods: In this cross-sectional study, children who were 3-12 years old, on antiretroviral therapy and pre-pubertal
were recruited from a Family HIV Clinic in South Africa. Lipoatrophy was identified and graded by consensus
between two HIV pediatricians using a standardized grading scale. A professional dietician performed formal dietary
assessment and anthropometric measurements of trunk and limb fat. Previous antiretroviral exposures were
recorded. In a Dual-Energy X-ray Absorbtiometry (DXA) substudy body composition was determined in 42
participants.
Results: Among 100 recruits, the prevalence of visually obvious lipoatrophy was 36% (95% CI: 27%–45%).
Anthropometry and DXA measurements corroborated the clinical diagnosis of lipoatrophy: Both confirmed
significant, substantial extremity fat loss in children with visually obvious lipoatrophy, when adjusted for age and
sex. Adjusted odds ratio for developing lipoatrophy was 1.9 (95% CI: 1.3 - 2.9) for each additional year of
accumulated exposure to standard dose stavudine. Cumulative time on standard dose stavudine was significantly
associated with reductions in biceps and triceps skin-fold thickness (p=0.008).
Conclusions: The prevalence of visually obvious lipoatrophy in pre-pubertal South African children on antiretroviral
therapy is high. The amount of stavudine that children are exposed to needs review. Resources are needed to
enable low-and-middle-income countries to provide suitable pediatric-formulated alternatives to stavudine-based
pediatric regimens. The standard stavudine dose for children may need to be reduced. Diagnosis of lipoatrophy at
an early stage is important to allow timeous antiretroviral switching to arrest progression and avoid stigmatization.
Diagnosis using visual grading requires training and experience, and DXA and comprehensive anthropometry are
not commonly available. A simple objective screening tool is needed to identify early lipoatrophy in resource-
limited settings where specialized skills and equipment are not available.* Correspondence: innes@sun.ac.za; shbrowne@ucsd.edu
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Figure 2 Stigmatizing lipoatrophy in a child – side view.
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The introduction of antiretroviral therapy (ART) in sub-
Saharan Africa has been life saving. However, long-term
ART, particularly nucleoside reverse transcriptase inhibi-
tors, may result in disfiguring loss of subcutaneous fat,
termed lipoatrophy (Figures 1 and 2). Lipoatrophy looks
very similar to AIDS wasting syndrome, termed “Slims
disease” throughout Africa, and may confer the same
stigmatization [1]. In contrast to the developed world,
stigmatization due to HIV in communal sub-Saharan
African cultures may lead to loss of access to commu-
nally-held resources, specifically loss of housing, denial
of schooling, denial of healthcare, loss of employment or
livelihood, secondary stigmatization of family members
and physical violence [2,3]. ART-induced lipoatrophy
may not be reversible, since lipoatrophy involves apop-
tosis of adipocytes [4], as opposed to nutritional wasting
where adipocyte fat stores shrink but the cell survives.
Fear of developing lipoatrophy may cause caregivers
to become non-adherent with ART, leading to loss of
CD4 cells, subsequent opportunistic infection and pos-
sibly death. In multivariate logistic regression modeling,
fat distribution abnormalities due to ART were an inde-
pendent risk factor for subsequent non-adherence in
adults [5].
While lipoatrophy has been well described in Europe
and the United States of America, there is almost no
data on this condition in pre-pubertal children from
sub-Saharan Africa, despite over 90% of the 3.4 million
HIV-infected children worldwide living in sub-Saharan
Africa [6]. In South Africa alone, more than a half mil-
lion children under 15 years of age are HIV-infected [6]
and, despite reductions in vertical transmission, an add-
itional 59,000 new infections in children occur anually
[7]. South Africa has the largest antiretroviral treatment
program in the world, with an estimated 163,000 in-
fants and children on ART by August 2012 (personalFigure 1 Stigmatizing lipoatrophy in a child – front view.communication – South African National Department
of Health), and many more added each year [7]. These
children face a lifetime of ART exposure and cumulative
ART toxicities, extending into several decades. In addi-
tion, the rapid changes related to growth may make them
more sensitive than adults to drug-related changes in fat
metabolism. The severity and extent of lipoatrophy in
pre-pubertal children living in sub-Saharan Africa is
unknown [8].
We explored the prevalence and risk factors for lipoa-
trophy in a group of pre-pubertal South African children
on ART. We also correlated the visual diagnosis of lipoa-
trophy with objective anthropometric measurements
of body fat in the whole group, and with Dual Energy
X-ray Absorptiometry (DXA) findings in a subgroup.
Methods
The Family Clinic for HIV at Tygerberg Children’s Hos-
pital is a public sector clinic providing ART to infants
and children from the Northern suburbs of Cape Town.
In this cross-sectional study, children who were 3–12
years old, on antiretroviral therapy and pre-pubertal
were recruited. Pre-pubertal status was determined using
Tanner staging. Using review of our electronic health
record database, we identified 190 subjects that poten-
tially met inclusion criteria. Of these, 124 attended clinic
during the study period and could be approached for
screening. A total of 121 provisionally agreed to partici-
pate, but 21 did not attend the study visit nor did they
respond to attempts at further contact. One hundred
subjects were finally recruited. There was no difference
in demographic characteristics of the 100 enrolled sub-
jects and the 90 who were not recruited (p>0.20 for age,
gender, cumulative time on standard dose stavudine and
CD4). Lipoatrophy was identified and graded by con-
sensus between two HIV pediatricians who were expe-
rienced in identifying lipoatrophy, using the following
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[9-11]: 0 – No fat changes; 1 – Possible minor changes,
noticeable only on close inspection; 2 - Moderate chan-
ges, readily noticeable to an experienced clinician or a
close relative who knows the child well; 3 – Major chan-
ges, readily noticeable to a casual observer. The sites ins-
pected were face, arms, legs and buttocks. Where the
assessment of the two investigators did not concur, the
change was graded as the lower score. Lipoatrophy was
defined as a score of 2 or 3.
Durations of previous antiretroviral exposures and
demographics were recorded from our electronic health
record database. HIV RNA and CD4 values were extrac-
ted from our central electronic laboratory results server.
Doses of antiretroviral drugs followed nationally pres-
cribed protocols. For stavudine this meant a minimum
of 1 mg/kg twice daily rounded up to the nearest prac-
tical dose. A professional dietician performed anthro-
pometric measurements of trunk and limb fat using a
non-stretchable tape-measure (model number F10-02DM,
Muratec KDS Corporation, Kyoto, Japan), a high-pre-
cision HarpendenW skin-fold caliper (Baty International,
West Sussex, United Kingdom), a ShorrBoardW stadiome-
ter (Shorr Productions, Maryland, USA), and a precision
weighing scale (model number UC-321, A&D Company,
Tokyo, Japan) which was calibrated daily. Measurements
included mid upper arm circumference, mid-thigh cir-
cumference, chest circumference, waist circumference, hip
circumference, biceps skin fold thickness (SFT), triceps
SFT, iliac crest SFT, sub-scapular SFT, mid-thigh SFT,
height and weight. The following ratios were derived:
waist to hip circumference ratio; body mass index; torso
to arm SFT ratio ([subscapular + iliac crest SFT] /
[biceps + triceps SFT]).
In a DXA substudy, as many DXA scans as logistical-
ly possible were performed using a Hologic Discovery
(Bedford, Massachusetts, USA) to objectively confirm
lipoatrophy. Trunk and limb fat mass, lean mass and fat
percentage were measured. Selection was semi-random
in that DXA was requested for all recruits; however, as
DXA is a rare commodity in the developing world, DXA
was not always available. There was no difference in
gender, cumulative time on standard dose stavudine or
CD4 between the 42 subjects who underwent DXA
scanning and the 58 who did not (p>0.50 for all). The
children who underwent DXA were marginally younger
than those who did not (7.1 versus 8.0 years, p=0.03).
Since very little is known about the normal pediatric
population in South Africa, additional normative data
was collected from healthy age-, gender- and socioeco-
nomically-matched HIV-uninfected children from the
same community who had been enrolled as part of a dif-
ferent study at our research unit [12]. We gathered an-
thropometry and DXA data from 57 children in order tosupplement what is known from published population
norms for age-related anthropometric and DXA vari-
ables, which are currently only derived from developed
country pediatric populations. This local normative data
appears in the results tables to assist the reader to gauge
the magnitude of the changes found in lipoatrophy-
affected children.
In univariate analyses, a t-test was used for parametric
data, Wilcoxon rank sum test was used for non-para-
metric data, and Fisher’s exact test was used for categor-
ical data. Non-parametric continuous data are quoted as
median (interquartile range), and parametric continuous
data are quoted as mean (standard deviation) or mean
(95% confidence interval) where appropriate. Multiple
logistic regression was used to study the risk factors as-
sociated with visually obvious lipoatrophy, adjusting for
age and CD4. Multiple linear regression models were
used to compare fat distributions captured by anthro-
pometry and DXA between children with and without
lipoatrophy, adjusting for age and sex. Skin-fold thick-
ness data was log-transformed before analysis. All statis-
tical analyses were performed using R version 2.10.0
(Bell Laboratories, New Jersey).
This study was designed in accordance with the guide-
lines of the International Conference on Harmonization
for Good Clinical Practice and with the Declaration of
Helsinki (version 2000), and approved and monitored
by the Ethics Committee for Human Research of the
Stellenbosch University, approval reference number N08/
11/349. Written informed consent was obtained from
each caregiver prior to participation, and informed assent
was obtained from capable children. All patient-related
data were stored in a password-secured database under a
patient identifying number and kept strictly confidential.
This study will directly benefit the community from which
the data is drawn by making recommendations about best
practice in public sector HIV clinics in South Africa.
Results
One hundred subjects were recruited. The prevalence of
visually obvious lipoatrophy was 36% (95% confidence
interval: 27% to 45%). Overall, children with and without
lipoatrophy had similar weight-for-age Z-score, height-
for-age Z-score, gender distribution, ethnic distribution,
WHO clinical stage, viral load and mean CD4 (see
Table 1). In children with lipoatrophy, face changes were
graded as more severe than limb changes in 11/36; the
same as limb changes in 24/36; and less severe than limb
changes in 1/36. In all cases, lipoatrophy changes were
deemed symmetrical. Twelve of the 36 cases had severe
changes (grade 3) similar to the child represented in
Figures 1 and 2. Six of the 64 children without lipoatro-
phy had a maximum lipoatrophy score at any site of
grade 1, and 58 had a score of zero at all sites.
Table 1 Comparison of HIV-infected children with and without visually obvious lipoatrophy
Children with
lipoatrophy N=36
Children without
lipoatrophy N=64
Univariate p-value
(two-tailed)
Multivariate p-value
(two-tailed)a
Nadir absolute CD4 before ART initiation with
standard deviation (SD)
681 (493) 886 (650) 0.29 –
Nadir CD4% before ART initiation (SD) 14% (8%) 19% (8%) >0.05 –
Maximum WHO clinical stage ever reached:
1 / 2 / 3 / 4
25% / 11% / 39% / 25% 17% / 9% / 46% / 28% 0.78 –
Median age at antiretroviral therapy (ART) 24 (9 – 43) 19 (9 – 37) 0.74 –
initiation, with inter-quartile range (IQR)
Median age at recruitment (months) (IQR) 89 (71 – 112) 71 (50 – 92) 0.001 0.75
Gender: Male / Female 21 (58%) / 15 (42%) 31 (48%) / 33 (52%) 0.41 –
Mean weight for age Z-score (SD) −1.1 (1.1) −0.9 (1.1) 0.39 –
Mean height for age Z-score (SD) −1.3 (1.2) −1.4 (1.1) 0.49 –
Mean body mass index Z-score (SD) −0.62 (1.00) −0.04 (1.08) 0.008 –
Absolute CD4 at recruitment (SD) 1296 (598) 1223 (631) 0.57 –
CD4% at recruitment (SD) 35% (7%) 32% (9%) 0.03 0.34
Mean current log10 viral load (SD) 1.98 (0.45) 2.23 (0.83) 0.10 –
Proportion on 2nd line therapy, defined as switch
of ≥2 antiretroviral drugs
8% 6% 0.58 –
Any antiretroviral exposure, median months (IQR) 56 (44 – 75) 43 (25 – 60) 0.002 0.52
Stavudine, median months (IQR) 41 (27 – 48) 30 (7 – 49) 0.02 0.002b
Lamivudine, median months (IQR) 52 (41 – 72) 41 (25 – 58) 0.01 0.66
Lopinavir/r, median months (IQR) 26 (0 – 56) 36 (6 – 51) 0.58 0.82
Efavirenz, medianc months (IQR) 0 (0 – 44) 0 (0 – 4) 0.003 0.48
a Variables with dashes were not included in the multivariate model.
b Adjusted odds ratio: 1.9 (95% CI: 1.3 - 2.9) for each additional year of accumulated exposure.
c Since fewer than half of the subjects in each group had been exposed to efavirenz, the median efavirenz exposure in both groups was 0 months. Mean
efavirenz exposure was 23 months in HIV positive with lipoatrophy versus 7 months in HIV positive without lipoatrophy.
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time on ART, time on standard dose stavudine, cumula-
tive lamivudine exposure, cumulative efavirenz exposure,
and greater age were associated with visually obvious li-
poatrophy. Zidovudine and didanosine were not inclu-
ded in the analysis as too few children had been exposed
to these drugs. WHO clinical stage did not correlate
with the presence or absence of lipoatrophy (p=0.78). A
multivariate logistic regression model controlling for age
and CD4%, incorporating all antiretroviral exposuresTable 2 Anthropometric measurements in children with and w
and sex
Children with
lipoatrophy, N=36
Childre
lipoatr
Biceps skin-fold thickness (SFT), mm, mean
with 95% confidence interval (95% CI)
4.2 (3.6 – 4.7) 5.3 (4.9
Triceps SFT, mm, mean (95% CI) 7.1 (6.2 – 7.9) 8.9 (8.3
Torso-to-arm SFT ratio: mean (95% CI)** 1.05 (0.96 – 1.14) 0.88 (0.
Waist-to-hip circumference ratio: mean
(95% CI)
0.97 (0.96 – 0.99) 0.95 (0.
* p-value compares HIV-infected children with and without lipoatrophy.
** Torso to arm SFT ratio = (subscapular + iliac crest SFT) / (biceps + triceps SFT).found significant in the univariate analysis, identified
cumulative time on standard dose stavudine as the pre-
dominant risk factor independently associated with lipo-
atrophy (adjusted odds ratio = 1.9 for each additional
year of accumulated exposure to standard dose stavu-
dine; 95% CI: 1.3 to 2.9; p=0.002), while efavirenz and
lamivudine were no longer associated. Abacavir expos-
ure was not included in the multivariate model as it was
only used for children who had developed a complica-
tion of stavudine therapy. Cumulative time on standardithout visually obvious lipoatrophy, adjusted for age
n without
ophy, N=64
HIV-uninfected local
population norms, N=57
p-value, adjusted for
age and sex (two-tailed)*
– 5.7) 5.5 (5.0 – 5.9) 0.002
– 9.6) 8.7 (8.1 – 9.4) <0.001
81 – 0.94) 0.84 (0.78 – 0.91) 0.002
93 – 0.96) 0.91 (0.90 – 0.93) 0.009
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tions in biceps and triceps SFT (p=0.008). Thirty-five
of the 36 children with lipoatrophy and 53 of the 64
children without lipoatrophy had ever been exposed to
stavudine, and 51/64 (80%) of children without lipoatro-
phy were on stavudine-based regimens at recruitment.
Table 1 shows the comparative antiretroviral exposures
and data from the univariate and multivariate analysis.
All but one of the children with lipoatrophy had been
exposed to more than 18 months of stavudine therapy.
At the time of assessment, 29/36 children with lipoatro-
phy had been off stavudine for at least six months with
no resolution of their symptoms.
Adjusting for age and sex, anthropometrics confirmed
significant, substantial extremity fat loss in children with
visually obvious lipoatrophy (see Table 2). There were
no statistically significant differences in anthropometric
measures of fat amount and distribution between chil-
dren without lipoatrophy and the local HIV-uninfected
pediatric population. Biceps SFT, triceps SFT, torso-to-
arm SFT ratio and waist-to-hip circumference ratio cor-
related with maximum lipoatrophy grading score, giving
regression coefficients of 0.34 (0.17 to 0.65, p=0.002),
0.31 (0.17 to 0.59, p=0.0006), 3.36 (1.57 to 7.16, p=0.002)
and 4.23 (0.37 to 8.10, p=0.03) respectively when ad-
justed for age and sex.
In the DXA substudy, measures of fat amount and dis-
tribution confirmed significant, substantial extremity fat
loss in children with visually obvious lipoatrophy, when
adjusted for age and sex (see Table 3). There were no
statistically significant differences in DXA measures of
fat amount and distribution between children without
lipoatrophy and the local HIV-uninfected pediatric po-
pulation. Limb fat versus limb lean ratio, limb fat versus
total body weight ratio, limb fat versus body mass index
ratio and total limb fat (converted to kilograms) corre-
lated with maximum lipoatrophy grading score, giving re-
gression coefficients of −2.24 (−0.86 to −3.62, p=0.003), -0
.02 (−0.01 to −0.03, p=0.002), –0.015 (−0.006 to −0.024,
p=0.003) and −0.8 (−0. 3 to −1.4 grams, p=0.006) respect-
ively when adjusted for age and sex.Table 3 Dual Energy X-ray Absorptiometry measurements in
Children with
lipoatrophy, N=15
Chi
lipo
Limb fat versus limb lean ratio: mean with
95% confidence interval (95% CI)
0.36 (0.25 – 0.46) 0.62
Limb fat versus total body weight ratio: mean
(95% CI)
9.9 (8.5 – 11.4) 13.7
Limb fat versus body mass index ratio:
mean (95% CI)
0.12 (0.10 – 0.13) 0.15
Total limb fat, kg, mean (95% CI) 1.7 (1.4 – 2.1) 2.3
* p-value compares HIV-infected children with and without lipoatrophy.Discussion
This is the first data from sub-Saharan Africa to show
the severity and extent of antiretroviral-related lipo-
atrophy in children. Visually obvious lipoatrophy was
present in a third of pre-pubertal children on ART. Chil-
dren with visually obvious lipoatrophy had 25-40% less
extremity fat (depending on the choice of measurement)
than HIV-infected children without lipoatrophy. Chil-
dren with lipoatrophy were not sicker and did not start
ART at a different age, compared to those without lipoa-
trophy. Since cumulative time on standard dose stavu-
dine is the greatest risk factor for lipoatrophy, it is not
surprising that older children, who had amassed greater
stavudine exposure, had more lipoatrophy. Other poten-
tial confounding effects associated with the difference in
age were adjusted for in the multivariate model.
Although DXA and anthropometry may be more pre-
cise measures of subcutaneous fat amount and distribu-
tion, a visual grading scale was chosen as the primary
outcome measure in this study because the greatest dan-
ger of lipoatrophy in sub-Saharan Africa stems from
stigmatization. Subtle changes in fat distribution that are
not visually obvious are less relevant since they are un-
likely to result in stigmatization.
As there is evidence of a genetic determinant in li-
poatrophy [13], it is important to study lipoatrophy spe-
cifically in sub-Saharan African populations. Our data
suggest that the prevalence of visually obvious lipoatro-
phy in pre-pubertal South African children on ART is
higher than the prevalence among most non-African
cohorts (typically 10 to 20%) [9,11,14,15]. Earlier studies
from the developed world have included immigrant chil-
dren from sub-Saharan Africa living in Paris [14], Lon-
don [16] and Brussels [15], and found a lipoatrophy
prevalence of 11%, 8% and 20% respectively. In the lar-
gest and most comprehensive study to date, Alam et al.
[17] found a 28% prevalence in a cross-sectional study of
426 European children, including 85 pubertal and 154
post-pubertal children and 107 black children. The
authors of that study noted that their prevalence was
significantly higher than previous pediatric studies, inchildren with and without visually obvious lipoatrophy
ldren without
atrophy, N=27
HIV-uninfected local
population norms, N=34
p-value, adjusted for age
and sex (two-tailed)*
(0.54 – 0.70) 0.63 (0.56 – 0.70) <0.001
(12.7 – 14.8) 14.7 (13.7 – 15.7) <0.001
(0.14 – 0.17) 0.17 (0.16 – 0.19) 0.001
(2.1 – 2.6) 2.7 (2.4 – 2.9) 0.01
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dication-adherent HIV-infected children, and established
lipoatrophy changes are largely irreversible, prevalence
can be expected to increase progressively if incidence re-
mains constant. Alam et al. found that Caucasian rather
than African ethnicity was a risk factor for lipoatrophy.
However, none of our recruits were Caucasian and our
pre-pubertal South African group had a higher preva-
lence than Alam’s cohort. This is most likely due to
higher rates of stavudine exposure in our context. The
magnitude of this difference suggests that data from im-
migrant African populations in Europe cannot be extra-
polated to populations living in sub-Saharan Africa and
emphasizes how crucial it is to study sub-Saharan popu-
lations directly, as >90% of HIV-infected children live in
these regions.
Ten percent of the cohort reported by Alam et al. was
currently exposed to stavudine [17], compared to 62% of
ours. While Alam et al. found an association between
lipoatrophy and current stavudine exposure, our results
go one step further to show that the risk of lipoatrophy
increases progressively as exposure to stavudine accu-
mulates. This finding is in line with that of the Asian
cohort reported by Aurpibul et al., which found an in-
creasing prevalence of fat distribution abnormalities as
cumulative exposure to ART increased [11]. This is sig-
nificant since Asian cohorts have similar conditions to
sub-Saharan Africa in that malnutrition is common, ac-
cess to ART for children is incomplete, and stavudine
has been the most widely used first-line antiretroviral
agent.
The PACT 1045 study [18] compared morphologic
changes using DXA in HIV-positive children compared
to HIV-negative matched controls in a cross-sectional
study. DXA-measured total body and limb fat were
lower in the HIV-positive subjects than in the HIV-
negative group in models adjusted for race, disease stage,
weight, height and Tanner stage. Among HIV-infected
subjects, there was no difference in limb fat between
subjects who used non-nucleoside reverse transcriptase
inhibitors versus protease inhibitors. Duration and use
of nucleoside reverse transcriptase inhibitors (including
stavudine) were not evaluated in that study.
Objective anthropometric and DXA measurements
confirmed the clinical assessment of visually obvious
lipoatrophy. Thus, diagnosis of lipoatrophy in African
children by skilled visual assessment is reliable and,
whilst it requires specific training and experience, no
additional investigations are needed in a developing-
country context. In our context, specific training to
recognize lipoatrophy in children typically includes di-
dactic training followed by supervised practice in a clinic
setting over a period of time until competence is rea-
ched to the satisfaction of the trainer. However, basiccompetence might be gained through review of an array
of photographs of mild to moderate lipoatrophy at vary-
ing ages, combined with diligent vigilance during clinical
practice. The authors have not studied the adequacy of
photograph-based training.
The prevalence of visually obvious lipoatrophy in pre-
pubertal South African children on ART is higher than
previously anticipated, affecting a third of children on
ART. This is most likely due to more extensive use of
stavudine than elsewhere. Whilst ART is life-saving for
HIV-infected children, surveillance and early diagnosis
of lipoatrophy with appropriate drug-switches is critical.
The use of agents associated with potentially stigmatiz-
ing face and limb changes is undesirable. The antiretro-
viral agent most commonly associated with lipoatrophy
in adults is stavudine [19] and our findings substantiate
this in the pre-pubertal pediatric South African popula-
tion. The 2010 World Health Organization (WHO) anti-
retroviral guidelines advise that stavudine should be
phased out where possible. However, stavudine remains
within the nationally recommended pediatric first-line
ART guidelines for numerous developing countries. In
South Africa, stavudine was the first choice nucleoside
reverse transcriptase inhibitor for children, together with
lamivudine, from the beginning of the ART access pro-
gram in 2004 until 2010, when it was replaced with
abacavir. Current South African guidelines state that
children taking stavudine should continue unless side-
effects develop. Thus the majority of children treated for
HIV in South Africa remain on stavudine. The effect of
stavudine in causing lipoatrophy appears to be strongly
dose-related [20-23]. The current standard pediatric
dose of stavudine was determined by extrapolation from
the pharmacokinetic parameters of the adult dose of
40 mg twice daily using data from pediatric pharmacoki-
netic studies [24,25]. Those studies showed that an oral
dose of 1 mg/kg/dose twice daily in children under 30 kg
results in plasma exposure similar to that of an adult
over 60 kg taking 40 mg twice daily; and that an oral
dose of 0.5 mg/kg/dose twice daily in children results in
plasma exposure similar to that of an adult over 60 kg
taking 20 mg twice daily. In 2007 an influential review
by Hill et al. of evidence accumulated over the previous
15 years suggested that stavudine given at the dose of 20
or 30 mg twice daily leads to a significantly lower rate of
lipoatrophy and of other mitochondrial adverse effects
while maintaining excellent antiviral efficacy [20]. In re-
sponse, the World Health Organization advised that the
recommended adult dose be lowered from 40 to 30 mg
BD [26]. The children’s dose, however, has not yet been
reduced. Consequently children on stavudine continue
to be exposed to a disproportionately high dose, which
may result in more rapid accumulation of metabolic ad-
verse effects than adults on the reduced dose.
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in children on stavudine. For that reason, the global tran-
sition away from stavudine-based regimens has focused
on adult services, while children on stavudine-based re-
gimens have not received equal attention. Stavudine re-
mains the most commonly used pediatric antiretroviral in
sub-Saharan Africa. The Clinton Health Access Initiative
and UNITAID have worked since 2002 to improve anti-
retroviral drug supply chains for adult formulations in
sub-Saharan Africa by facilitating procurement and pro-
viding funding for purchases where necessary. Similar
efforts are critical to the successful transition away from
stavudine-based regimens for children.
Our study has the following limitations: we selected
subjects for enrollment based on meeting eligibility re-
quirements and having a routine clinic appointment dur-
ing the study-screening period. This could represent a
biased subset of all available subjects in our clinic popu-
lation, but there is no reason to think that temporal fac-
tors (when a subject had a clinic visit) would be related
to the study outcome of lipoatrophy. The relatively high
rate of drop-out from study screening to the actual stu-
dy visit could also bias the sample, but basic demograph-
ics were not different and logistic difficulties, due to
extreme poverty, often interfere with clinic attendance;
patients’ arrival for appointments is typically erratic.
Considering these obstacles, a sample size of 100 chil-
dren is a significant achievement. The subsets of recruits
exposed to zidovudine and other nucleoside reverse
transcriptase inhibitors were small, and did not allow
comment on their relationship to lipoatrophy. The two
clinicians who performed the visual assessment could
not be blinded to the children’s ART status, which may
have biased their assessment. However, since the chil-
dren were well-known, the clinicians had a longitudinal
perspective on which to base their assessment. DXA was
requested for all recruits; however, as DXA is a rare
commodity in the developing world, DXA was not al-
ways available. The possibility of selection bias in the
DXA substudy cannot be excluded.
As with the cohort reported by Alam et al., we are col-
lecting longitudinal data on our cohort, which will allow
calculation of incidence and will document the degree
and rate of regression after antiretroviral switching.
Conclusions
The prevalence of visually obvious lipoatrophy in pre-
pubertal South African children on antiretroviral therapy
is high, and is likely to continue rising as stavudine con-
tinues to be used extensively at an unnecessarily high
dose. The amount of stavudine that children are exposed
to needs review. Resources are needed to enable low-
and-middle-income countries to provide suitable pedia-
tric-formulated alternatives to stavudine-based pediatricregimens. The standard stavudine dose for children may
need to be reduced. Diagnosis of lipoatrophy at an early
stage is important to allow timeous antiretroviral swit-
ching to arrest progression and avoid stigmatization.
Diagnosis using visual grading requires training and ex-
perience, and DXA and comprehensive anthropometry
are not commonly available. A simple objective screening
tool is needed to identify early lipoatrophy in resource-
limited settings where specialized skills and equipment are
not available.
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